Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients ; volume:20 ; number:1 ; day:7 ; month:3 ; year:2018 ; pages:1-11 ; date:12.2018
Arthritis Research & Therapy ; 20, Heft 1 (7.3.2018), 1-11, 12.2018
- Creator
-
Takeuchi, Tsutomu
- Contributor
-
Yamanaka, Hisashi
Harigai, Masayoshi
Tamamura, Ryo
Kato, Yuichi
Ukyo, Yoshifumi
Nakano, Toshikazu
Hsu, Benjamin
Tanaka, Yoshiya
SpringerLink (Online service)
- DOI
-
10.1186/s13075-018-1536-9
- URN
-
urn:nbn:de:1111-201805133535
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:04 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Takeuchi, Tsutomu
- Yamanaka, Hisashi
- Harigai, Masayoshi
- Tamamura, Ryo
- Kato, Yuichi
- Ukyo, Yoshifumi
- Nakano, Toshikazu
- Hsu, Benjamin
- Tanaka, Yoshiya
- SpringerLink (Online service)
Other Objects (12)
Rheumatoid arthritis
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
Genome-oriented treatment strategies for autoimmune diseases
Usefulness of nailfold videocapillaroscopy for systemic sclerosis
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Associations between time in range and insulin secretory capacity in Japanese patients with type 2 diabetes
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial
Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study)
Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts
Rheumatoid arthritis
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
Genome-oriented treatment strategies for autoimmune diseases
Usefulness of nailfold videocapillaroscopy for systemic sclerosis
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Associations between time in range and insulin secretory capacity in Japanese patients with type 2 diabetes
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial
Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study)
Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts
Rheumatoid arthritis
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
Genome-oriented treatment strategies for autoimmune diseases
Usefulness of nailfold videocapillaroscopy for systemic sclerosis
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Associations between time in range and insulin secretory capacity in Japanese patients with type 2 diabetes
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial
Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study)